• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    7/20/23 5:32:20 PM ET
    $APVO
    $AZTR
    $BSGM
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APVO alert in real time by email

    Gainers

    • Evelo Biosciences (NASDAQ:EVLO) stock increased by 11.7% to $11.01 during Thursday's after-market session. Trading volume for this security closed at 524.2K, accounting for 68.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $206.8 million.
    • TFF Pharmaceuticals (NASDAQ:TFFP) shares moved upwards by 9.28% to $0.4. The market value of their outstanding shares is at $14.5 million.
    • Anitra (AMEX:AZTR) stock increased by 7.49% to $4.3. The market value of their outstanding shares is at $51.9 million.
    • Intensity Therapeutics (NASDAQ:INTS) stock moved upwards by 6.74% to $6.49. The market value of their outstanding shares is at $88.8 million.
    • Aptevo Therapeutics (NASDAQ:APVO) stock moved upwards by 6.66% to $1.12. At the close, Aptevo Therapeutics's trading volume reached 806.7K shares. This is 580.5% of its average volume over the last 100 days. The company's market cap stands at $8.4 million.
    • Mesoblast (NASDAQ:MESO) stock rose 6.58% to $5.02. The market value of their outstanding shares is at $816.9 million.

    Losers

    • BioSig Technologies (NASDAQ:BSGM) shares fell 7.2% to $1.29 during Thursday's after-market session. Today's trading volume for this security ended up closing at 10.7 million shares, which is 3717.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $95.4 million.
    • Trinity Biotech (NASDAQ:TRIB) shares decreased by 6.67% to $0.98. The market value of their outstanding shares is at $37.4 million.
    • Novan (NASDAQ:NOVN) shares decreased by 6.18% to $0.15. Trading volume for this security closed at 758.4K, accounting for 86.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.2 million.
    • Trxade Health (NASDAQ:MEDS) stock declined by 5.37% to $9.0. The company's market cap stands at $6.1 million.
    • Cingulate (NASDAQ:CING) stock declined by 5.21% to $0.73. The company's market cap stands at $8.5 million.
    • Intuitive Surgical (NASDAQ:ISRG) stock decreased by 4.54% to $331.88. Trading volume for this security closed at 449.8K, accounting for 27.4% of its average full-day volume over the last 100 days. The company's market cap stands at $116.2 billion. As per the news, the Q2 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APVO
    $AZTR
    $BSGM
    $CING

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    3/11/2026$590.00Neutral → Buy
    Citigroup
    Intuitive Surgical Inc.
    $ISRG
    1/27/2026$660.00Buy
    TD Cowen
    Intuitive Surgical Inc.
    $ISRG
    12/11/2025$635.00Buy → Neutral
    Citigroup
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    Intuitive Surgical Inc.
    $ISRG
    7/23/2025Buy → Hold
    Erste Group
    Mesoblast Limited
    $MESO
    7/18/2025Buy → Hold
    Jefferies
    Intuitive Surgical Inc.
    $ISRG
    6/9/2025$440.00Hold → Sell
    Deutsche Bank
    Intuitive Surgical Inc.
    $ISRG
    6/5/2025Hold → Buy
    Erste Group
    More analyst ratings

    $APVO
    $AZTR
    $BSGM
    $CING
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

    Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second quarter of 2027IT-01 Study manuscript of INT230-6 used alone in 64 refractory metastatic cancer patients published in the Lancet's journal eBioMedicine, including data for disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safetyFavorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 StudySHELTON, Conn., March 27, 2026 /PRNew

    3/27/26 4:12:00 PM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems

    SAN CARLOS, Calif., March 24, 2026 /PRNewswire/ -- Sonder Capital, a healthcare venture capital firm investing in companies revolutionizing the standard of care, today announced the closing of its second fund, Futures II. The fund includes participation from Mayo Clinic and Sutter Health, reflecting their collective interest in innovative technologies that have the potential to advance the future of patient care by enhancing access, improving quality and transforming the overall patient experience."Through our second fund we'll continue enabling the next wave of companies and he

    3/24/26 11:03:00 AM ET
    $ISRG
    $PRCT
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

    New US patent 12,496,345 strengthens the existing portfolioPatents now granted in 41 countries protect the Company's novel intratumoral technology, including lead compound INT230-6SHELTON, Conn., March 24, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (NASDAQ:INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, provided an update on its patent portfolio including the recent issuance in December 2025 of a new US patent in the U.S., US P

    3/24/26 8:00:00 AM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APVO
    $AZTR
    $BSGM
    $CING
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider George Gregory

    3 - MESOBLAST LTD (0001345099) (Issuer)

    3/23/26 8:00:19 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Salva Francisco D.

    4 - Azitra, Inc. (0001701478) (Issuer)

    3/20/26 4:30:30 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Krause Philip R.

    3 - MESOBLAST LTD (0001345099) (Issuer)

    3/18/26 5:44:56 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APVO
    $AZTR
    $BSGM
    $CING
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    $AZTR
    $BSGM
    $CING
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intuitive Surgical upgraded by Citigroup with a new price target

    Citigroup upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $590.00

    3/11/26 8:28:54 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    TD Cowen initiated coverage on Intuitive Surgical with a new price target

    TD Cowen initiated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $660.00

    1/27/26 8:46:58 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Intuitive Surgical downgraded by Citigroup with a new price target

    Citigroup downgraded Intuitive Surgical from Buy to Neutral and set a new price target of $635.00

    12/11/25 8:53:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $APVO
    $AZTR
    $BSGM
    $CING
    SEC Filings

    View All

    Intensity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

    3/27/26 4:13:39 PM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Cingulate Inc.

    424B3 - Cingulate Inc. (0001862150) (Filer)

    3/27/26 4:01:35 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Intensity Therapeutics Inc.

    10-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

    3/27/26 4:01:10 PM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APVO
    $AZTR
    $BSGM
    $CING
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast's medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs i

    3/11/26 7:21:39 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application

    11/13/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intel Appoints Dr. Craig H. Barratt to Board of Directors

    Intel Corporation (NASDAQ:INTC) today announced that Craig H. Barratt, Ph.D., 63, has been appointed to its board of directors, effective immediately. Dr. Barratt will serve as an independent director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110908011/en/Dr. Craig H. Barratt joins Intel's board as an independent director. "Craig is a highly accomplished technology leader with a proven ability to innovate, scale, and transform businesses," said Lip-Bu Tan, Intel CEO. "He is a seasoned semiconductor executive with experience at multiple leading-edge technology companies, which will be invaluable as we continue to execute

    11/10/25 6:21:00 PM ET
    $ALAB
    $INTC
    $ISRG
    Semiconductors
    Technology
    Industrial Specialties
    Health Care

    $APVO
    $AZTR
    $BSGM
    $CING
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by TFF Pharmaceuticals Inc.

    SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

    11/19/24 4:05:58 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    $AZTR
    $BSGM
    $CING
    Financials

    Live finance-specific insights

    View All

    Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

    Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech's New York Reference Laboratory DUBLIN and NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a global diagnostics company, today announced successful results from a clinical study of a new, enhanced version of its EpiCapture™ prostate cancer test, engineered to deliver higher precision risk prediction of aggressive prostate cancer. This next-generation version of EpiCapture™ utilizes machine learning tools that integrate additional patient features, including patient ethnicity in conjunction with the DNA biomarkers

    3/23/26 9:23:07 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

    DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into a collaboration agreement with the University at Buffalo, New York ("UB"). The partnership focuses on advancing and commercializing a suite of proprietary biomarkers for the earlier and more accurate detection of Sjögren's Syndrome, one of the most common but underdiagnosed autoimmune diseases. This collaboration is a key strategic milestone in the continued expansion of Trinity Biotech's New York State Department of Health – appr

    3/18/26 8:30:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

    Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has commenced the commercial rollout in Brazil of its updated laboratory blood glucose monitoring solution, the next‑generation HbA1c column system for its Premier Hb9210™ platform, following receipt of local regulatory approval. This approval enables the introduction of the Company's upgraded boronate affinity column

    3/12/26 9:00:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care